# A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine

> **NCT02018874** · PHASE1 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 52 (actual)

## Conditions studied

- Solid Tumors and Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** LY2780301
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02018874
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2016-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02018874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02018874, "A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02018874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*